Advances in the management of diabetic macular oedema based on evidence from the Diabetic Retinopathy Clinical Research Network.
- Author:
Lik Thai LIM
1
;
Seen Nee CHIA
1
;
Elliott Yann AH-KEE
2
;
Nejia CHEW
3
;
Manish GUPTA
1
Author Information
- Publication Type:Journal Article
- Keywords: DRCR.net review; diabetic macular oedema; treatment
- MeSH: Adrenal Cortex Hormones; therapeutic use; Bevacizumab; therapeutic use; Biomedical Research; organization & administration; Diabetic Retinopathy; therapy; Disease Management; Disease Progression; Humans; Light Coagulation; Macular Edema; therapy; Ranibizumab; therapeutic use; Retina; pathology; Tomography, Optical Coherence; Triamcinolone; therapeutic use; Vascular Endothelial Growth Factor A; antagonists & inhibitors; Visual Acuity; Vitrectomy
- From:Singapore medical journal 2015;56(5):237-247
- CountrySingapore
- Language:English
- Abstract: The Diabetic Retinopathy Clinical Research Network (DRCR.net) performs studies on new treatments for diabetic retinopathy. This review aims to summarise recent findings from DRCR.net studies on the treatment of diabetic macular oedema. We performed a PubMed search of articles from the DRCR.net, which included all studies pertaining to the treatment of diabetic maculopathy. The main outcome measures were retinal thickening as assessed by central subfield thickness on optical coherence tomography and improvement of visual acuity on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Findings from each study were divided into modalities of treatment, namely photocoagulation, bevacizumab, triamcinolone, ranibizumab and vitrectomy. While modified ETDRS focal/grid laser remains the standard of care, intravitreal corticosteroids or anti-vascular endothelial growth factor agents have also proven to be effective, although they come with associated side effects. The choice of treatment modality for diabetic macular oedema is a clinical judgement call, and depends on the patient's clinical history and assessment.
